Corvus Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company pioneering the development of ITK (interleukin-2 inducible T-cell kinase) inhibition as a novel approach to immunotherapy. The company's lead product candidate is soquelitinib (formerly CPI-818), an investigational, oral, selective small molecule ITK inhibitor. Soquelitinib is designed to target T-cell activation, receptor signaling, and differentiation, positioning it as a potential 'pipeline-in-a-product' with applications spanning both oncology and immune-mediated inflammatory diseases. Corvus is currently evaluating soquelitinib in a registrational Phase 3 clinical trial for relapsed/refractory peripheral T-cell lymphoma (PTCL) and a randomized, placebo-controlled Phase 2 clinical trial for moderate-to-severe atopic dermatitis. The company's broader pipeline also includes other clinical-stage candidates such as mupadolimab (CPI-006) and ciforadenant (CPI-444) targeting various cancer indications.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Enrolling patients in the SIERRA1 Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the safety, tolerability, and preliminary efficacy of oral soquelitinib in approximately 200 patients with moderate-to-severe atopic dermatitis who have failed at least one prior topical or systemic therapy.
Expected impact: Aims to replicate Phase 1 findings showing dose-dependent EASI and IGA responses and durable, drug-free remissions without rebound.
Conducting a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). The randomized, controlled study evaluates soquelitinib against standard-of-care chemotherapy (belinostat or pralatrexate) in approximately 150 patients.
Expected impact: Potential to deliver the first FDA-approved agent for relapsed PTCL based on a randomized trial, addressing a high unmet medical need.
Expanding the clinical pipeline of soquelitinib into additional inflammatory and autoimmune indications, including plans to initiate Phase 2 trials in hidradenitis suppurativa (HS) and asthma, alongside next-generation ITK inhibitor preclinical candidates.
Expected impact: Establishes ITK inhibition as a broad platform technology for selective T-cell modulation across multiple multi-billion dollar markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Co-founded by Corvus in 2020 to develop and commercialize its clinical-stage pipeline (soquelitinib, ciforadenant, mupadolimab) in Greater China and obtain global rights to preclinical BTK inhibitor programs. Corvus holds a 49% equity stake and designated three of five board seats.
Terms: Corvus participated in a new $13.5 million financing round for Angel Pharma in June 2026, investing $5 million to support parallel clinical trials of soquelitinib in China.
Collaborating on a Phase 2 clinical trial evaluating soquelitinib for the treatment of autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disorder characterized by immune dysregulation.
Terms: The trial is conducted and led by NIAID/NIH investigators, leveraging public research infrastructure to expand soquelitinib's clinical footprint.